Preliminary Program. Subject to Changes & Updates.
Time | Session |
---|---|
08:30 | Welcome Coffee |
09:15 | Opening Remarks – Organizers |
09:20 | Keynote I: Mathias Vormehr – Senior Director Cancer Vaccines – BioNTech – “mRNA vaccines for the treatment of cancer” |
10:00 | Company Presentations I: Covadonga Pañeda – Altamira Therapeutics- “TBA” Irma Ochigava – CapCoBio – “TBA” Constance Ciaudo Beyer – DeepLife – “TBA” Dominik Witzigmann – NannoVation Therapeutics – “TBA” TBA – Sylentis – “TBA” More to be announced |
10:30 | Coffee Break |
11:00 | Short Talk on Rare Disease Clinical Projects: Matias Wagner – Institute of Human Genetics, Klinikum rechts der Isar, Technical University Munich – “TBA” |
11:10 | Panel I – Medical Development: Marc Abramowicz – Professor & Head, Genetic Medicine, University Hospital Geneva Jasmin Barman-Aksözen – Triemli Hospital & University of Zurich Matias Wagner – Institute of Human Genetics, Klinikum rechts der Isar, Technical University Munich Annemieke Aartsma-Rus – Professor of Human Genetics – University of Leiden |
11:40 | Poster Flash Talks |
12:00 | Lunch & Poster Session & Networking & Sponsor Presentations |
14:00 | Keynote II: Annemieke Aartsma-Rus – Professor of Human Genetics – University of Leiden – “From Duchenne exon skipping to N=1 treatment: Applying lessons learned for (very) rare disease patients” |
14:40 | Young Scientists Career Talks: Mateusz Mendel – Senior Scientist Lead Discovery – Roche |
15:00 | Academic Talks Johannes Häberle – University Children’s Hospital Zurich & University of Zurich – “TBA” Rory Johnson – UC Dublin & University of Bern – “TBA” Deborah Stroka – Department for BioMedical Research, University of Bern – “TBA” |
15:40 | Coffee Break |
16:10 | Company Presentations II TBA – Roche – “TBA” Troels Koch – MiNA Therapeutics – “TBA” |
17:00 | Panel II – Patients, Society & RNA Medicine Panelists TBA |
17:30 | Concluding Remarks – Organizers |
17:35 | Apéro |